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Coumarins	 are	 natural	 compounds	 that	 have	 various	 physiological	 and	 therapeutic	
properties,	 making	 them	 pharmacologically	 important.	 	 Combretastatin	 A-4	 (CA-4)	 is	 a	
microtubule-binding	agent	that	has	potent	cytotoxic	effects	against	human	cell	lines.		In	CA-
4	the	trimethoxyarene	moiety	plays	a	crucial	role	in	its	carcinopreventive	effect.		Thus,	we	




The	 coupling	partners,	 4-azidocoumarins,	 required	 for	making	 these	 combretacoumarins	




BtO–	at	 the	C-4	position,	 leading	to	the	desired	4-azidocoumarins.	 	The	mechanism	of	 the	
formation	 of	O4-(benzotriazolyl)	 derivative	 of	 4-hydroxycoumarin	 has	 been	 investigated	
using	31P	NMR,	and	results	indicate	that	a	coumarin-derived	phosphonium	ion	intermediate	
	 VIII	
is	 formed	 en	 route	 to	 the	 O4-(benzotriazolyl)coumarin	 derivative.	 	 The	 second	 coupling	
partner,	 5-ethynyl-1,2,3-trimethoxybenzene,	 was	 synthesized	 from	 3,4,5-
trimethoxybenzaldehyde	 using	 the	 Corey-Fuchs	 olefination	 procedure.	 	 After	 various	
optimizations,	 it	 was	 found	 that	 the	 best	 conditions	 for	 the	 synthesis	 of	 the	
combretacoumarins	 is	 the	use	of	 the	 catalyst	 [(MeCN)4Cu]PF6,	 in	CH2Cl2/MeOH	with	2,6-
lutidine	as	an	additive,	at	50	oC.		Results	from	a	reactivity	comparison	between	PhN3	and	4-
azidocoumarin	 under	 the	 aforementioned	 reaction	 conditions	 showed	 that	 PhN3	 is	more	
reactive.	 	 In	 order	 to	 investigate	 the	 difference	 in	 reactivities	 of	 PhN3	 and	 the	 4-






coefficients	 for	 the	 N3.	 	 Additionally,	 the	 combretacoumarins	 were	 evaluated	 for	 their	
antiproliferative	 and	 antiviral	 activities.	 	 However,	 combretacoumarins	 had	 solubility	













































































































































This	 disease	 is	 characterized	 by	 an	 uncontrolled	 proliferation	 of	 cells	 caused	 by	 the	
dysfunction	 of	 vital	 enzymes	 and	 proteins	 responsible	 for	 regulating	 cell	 division	 and	
growth.3,4		With	this	as	a	basis,	current	antitumor	drugs	are	designed	to	inhibit	or	terminate	
the	 aforementioned	 mechanisms	 of	 cancer.	 	 Currently,	 the	 most	 effective	 and	 efficient	





the	 patient.6,7	 	 The	 search	 for	 efficacious,	 novel	 therapeutics	 against	 cancers	 is	 a	 major	
scientific	 endeavor.	 	 Studies	 have	 shown	 that	 compounds	 such	 as	 coumarin	 and	 its	
derivatives,	as	well	as	microtubule-binding	agents	(MBAs),	specifically	combretastatin	A-4,	













structure	 can	contain	 substituents),	 furanocoumarins	 (compound	2	 is	 furanocoumarin,	 it	
contains	a	furanyl	ring	fused	to	coumarin),	pyranocoumarins	(compound	3	is	Seselin,	it	is	a	
2,2-dimethyl-2H-pyran	 fused	 to	 coumarin),	 and	 the	 pyrone-substituted	 coumarin	
(compound	4	is	Coumadin),	a	known	anticoagulant.11		The	simplest	member,	coumarin	(1	in	
Figure	1,	2H-chromen-2-one),	has	been	found	to	be	pharmacokinetic	properties	due	to	its	




Coumarin	 and	 its	 derivatives	 have	 proven	 to	 have	 physiological	 and	 therapeutic	
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Other	 studies	 have	 shown	 that	 coumarin	 derivatives	 can	 function	 as	 oral	
anticoagulants.13		These	derivatives	 inhibit	 the	coagulation	cascade	pathway	by	hindering	
the	 formation	 of	 active	 vitamin	 K,	 an	 essential	 vitamin	 needed	 for	 the	 synthesis	 of	
prothrombin.		Prothrombin	is	a	protein	found	in	blood	plasma,	and	its	active	form,	thrombin,	
aids	 in	blood	clotting.	 	Obstruction	of	prothrombin	 formation	occurs	due	to	the	coumarin	





against	 cancer	 and	 alleviating	 adverse	 side	 effects	 from	 radiotherapy.8	 	 The	 therapeutic	
utilities	of	coumarins	are	dependent	upon	the	substituents	present	and	their	positions	on	
the	 ring.14	 	 Substantial	 effort	 has	 been	 directed	 towards	 introducing	 potential	
pharmacophore	moieties	in	the	3,	4	and	7	positions	of	the	coumarin.5		Substitutions	at	these	
sites	have	been	observed	to	yield	coumarins	with	potential	anticancer	properties.		Data	from	
biological	 studies	 have	 shown	 that	 promising	 coumarin	 derivatives	 include	 3,4-fused	
coumarins,	coumarin	hybrids,	and	O-substituted	analogues	of	7-hydroxycoumarins.5		Studies	
have	 also	 shown	 that	 the	 following	 modifications	 on	 coumarins	 are	 also	 very	 effective	
against	 cancer	 cells:	 amide,	 hydrazide	 or	 aryl	 moieties	 at	 the	 C-3	 position,	 and	 C-4	
substitutions	that	include	a	methylene	linker	joining	another	moiety	or	compound	with	the	
coumarin.5	 	 These	 derivatives	 have	 been	 observed	 to	 display	 antitumor	 activities	 via	
hindering	mechanisms	that	promote	cancer	formation.5		Some	of	these	antitumor	activities	
 4 




In	 vitro	 anti-proliferative	 activity	 has	 been	 observed	 for	 6-nitro-7-hydroxycoumarin	 (6,	
Figure	 2),	 6,7-dihydroxycoumarin	 (7,	 Figure	 2)	 and	 6-methoxy-7-hydroxycoumarin	 (8,	
Figure	2).16–18	 	 In	vitro	 studies	have	shown	that	6	exhibits	anti-proliferation	activities	via	
activation	of	mitogen-activated	protein	kinase	(MPAK,	p38),	stress-activated	protein	kinase	
(SAPK),	 and	 p21WAF1/CIP1	 cyclin-dependent	 kinase	 inhibitor.16	 	 Programmed	 cell	
termination	of	leukemic	cells	has	been	observed	by	the	use	of	esculetin	(7)	and	scopoletin	
(8).17,18	 	 Monastrol	 (9,	 Figure	 2)	 is	 a	 cell-permeable	 molecule	 that	 inhibits	 the	 spindle	
apparatus,	thereby,	impeding	mitosis.19,20		A	coumarin	derivative	of	monastrol,	10	(Figure	
2),	has	been	tested	in	vitro	against	MCF7,	T47D,	and	MDAMB231	cell	lines.		The	results	show	





































In	 a	 multitude	 of	 cell	 lines,	 C-4	 substituted	 coumarin	 derivatives	 demonstrate	
abundant	 cytotoxic	 activities.22	 	 Some	 of	 the	 activities	 of	 such	 compounds	 include:	 (a)	
inhibition	 of	 aromatase,	 an	 enzyme	 responsible	 for	 transforming	 androgen	 to	 estrogen,	
thereby	targeting	breast	cancer,23	(b)	prevention	of	DNA	replication	by	insertion	and	binding	
with	fragmented	DNA	originating	from	tumors	called	circulating	tumor	DNA	(ct-DNA),24	(c)	





In	2010,	Belluti	et	al.	modeled	hybrid	 compounds	based	on	 simple	 coumarins	and	
stilbenes	in	order	to	access	novel	carcinopreventive	agents.26		The	rationale	stemmed	from	
the	 fact	 that	 both	 coumarins	 and	 stilbene	 derivatives	 are	 reported	 to	 have	 anticancer	
activities.	 	 To	 expand	 upon	 the	 latter,	 prior	 studies	 had	 shown	 that	 a	 phytochemical,	




their	 results	 indicated	 that	 the	 synthesized	 compounds	were	more	 effective	 against	 lung	







benefits	 of	 the	 triazole	 ring	 are	 as	 follows:	 increased	 solubility	 for	 the	 compound,	 and	
increased	 interaction	 with	 other	 molecules	 via	 hydrogen	 bonds	 and	 dipole-dipole	
interactions.31		The	triazole	ring	can	also	function	as	an	amide	group	mimic	due	to	its	stability	
against	many	chemical	reactions.32		It	also	has	aromatic	character,	and	is	typically	inert	(even	
at	 elevated	 temperatures)	 to	 hydrolytic	 and	 redox	 conditions.33	 	 All	 these	 advantageous	




One	 example	 of	 4-(1,2,3-triazol-1-yl)coumarin	with	 anticancer	 activity	 is	 4-(4-((4-
fluorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)-7-methoxy-2H-chromen-2-one	(15	 in	Figure	
4).38		For	this	study,	inhibition	of	tumor	cell	proliferation	via	cell-cycle	arrest	and	apoptosis	
was	 observed	more	 prominently	with	 this	 compound	 than	with	 other	 4-(1,2,3-triazol-1-






















In	 2017,	 a	 study	 had	 been	 conducted	 to	 investigate	 the	 antioxidative	 and	
antiproliferative	 properties	 of	 compounds	 composed	 of	 coumarins	 linked	 to	 a	 non-
substituted,	hydroxy-,	and	methoxy-substituted	phenyl	rings	via	a	1,2,3-traizole	moiety.39		
Results	 obtained	 showed	 that	 compounds	16,	 17,	 18,	 and	19	 (Figure	 5)	were	 the	most	
potent	compounds	in	terms	of	antioxidative	properties,	and	also	had	unselective	inhibition	
of	cell	growth	against	normal	kidney	cells	of	Madin	Darby	canine,	MDCK1,	blast	crisis	cells	of	



































































2]	 azide-alkyne	 cycloaddition	 (CuAAC)	 reaction,	 a	 class	 of	 reactions	 independently	
developed	 by	 the	 research	 groups	 of	 Meldal	 and	 Sharpless.40,41	 	 This	 reaction	 leads	
exclusively	to	the	1,4-disubstituted	1,2,3-triazole	regioisomers,	as	opposed	to	the	mixture	of	
1,4-	and	1,5-regioisomers	that	are	obtained	from	the	classical	Huisgen	ligation.42	
 Historically,	 1,2,3-triazoles	were	 initially	 synthesized	 in	 1893	 by	A.	Michael	 using	








	 In	 2002,	 a	 variation	 of	 the	 Huisgen	 ligation	 was	 reported	 by	 two	 independent	
research	groups,	Meldal	in	Denmark,	and	Sharpless	and	Fokin	in	the	U.S.40,41		They	performed	
azide/alkyne	 cycloaddition	 using	 copper	 catalysts.	 	 Results	 obtained	 showed	 that	 the	
copper(I)-catalyzed	 [3	 +	 2]	 azide-alkyne	 cycloaddition	 (CuAAC)	 reaction	 (Scheme	 2)	





























alkyne	 via	 ruthenium	 cyclopentadienyl	 complexes	 (Scheme	 3).	 	 When	 compared	 to	 the	





Due	 to	 the	 aforementioned	 advantages,	 CuAAC	 has	 become	 a	 very	 prominent	
synthetic	method,	and	is	used	in	other	disciplines	such	as	medicinal,	surface,	and	polymer	
chemistry.34		However,	mechanistic	studies	involving	copper-catalyzed	reactions	have	been	









































































an	 intramolecular	 reaction	 results	 in	 the	 formation	 of	 the	 dinuclear	 copper	 species,	 27.		
Fokin	et	al.	has	shown	evidence	on	the	existence	of	a	dinuclear	copper	species	via	time-of-
flight	 mass	 spectrometry	 (TF-MOS)	 and	 copper	 isotope	 labelling.49	 	 Additional	 studies	
involving	 real-time	 heat-flow	 calorimetric	 tracking	 has	 shown	 that	 the	 addition	 of	 a	
copper(I)	catalyst	to	a	s-bound	copper(I)-acetylide	drastically	increased	its	rate	of	reaction	
with	organic	azides,	 thereby,	 leading	to	the	 formation	of	 the	cycloaddition	complex	more	
efficiently.49		Then,	the	secondary	copper	atom	along	with	its	ligand	is	eliminated,	resulting	
in	the	formation	of	a	cuperated	triazole	28.		Nolte	et	al.	proved	the	existence	of	such	a	species	
in	 2007	 when	 they	 isolated	 and	 characterized	 compound	 31	 (Figure	 7)	 via	 X-ray	







































There	 are	 two	 types	 of	 MBAs:	 one	 type	 consists	 of	 agents	 which	 stimulate	
polymerization	 of	 tubulins	 and	 stabilize	 microtubules,	 and	 the	 other	 which	 stimulate	
depolymerization	 of	 tubulins	 and	 destabilize	 microtubules.54	 	 They	 have	 the	 ability	 to	
stimulate	 cell	death	by	preventing	 chromosome	segregation	via	 inhibiting	proper	mitotic	
spindle	assembly	during	mitosis.		One	of	the	most	prominent	drug	that	has	been	studied	as	
a	MBA	is	combretastatin	A-4	(32,	Figure	8,	CA-4).56		This	phytochemical	compound	has	been	
obtained	 from	 Combretum	 caffrum,	 a	 tree	 in	 South	 Africa.57	 	 CA-4	 inhibits	 microtubule	
formation	by	inhibiting	tubulin	polymerization	via	binding	to	the	colchicine	(33,	Figure	8)	
















for	 more	 efficient	 biological	 studies.65	 This	 disodium,	 water	 soluble	 derivative	 of	 CA-4	









































with	 these	 compounds	 revealed	 that	 the	 1,5-disubstituted	 compounds	 had	 better	
cytotoxicity	than	1,4-disubstituted	1,2,3-triazoles.		The	results	obtained	also	indicated	that	
shorter	 bridge	 lengths	 between	 the	 two	 rings	 increased	 cytotoxicity	 since	 triazoles	
synthesized	from	phenyl	azides	were	more	potent	than	those	derived	from	benzyl	azides.		
The	 most	 effective	 compounds	 with	 respect	 to	 cytotoxicity	 included	 compounds	 37–44	
(Figure	10)	with	substituents	at	C-3	in	the	B	ring.		When	compared	to	other	compounds	in	
























On	the	basis	of	 the	 foregoing	sections,	where	the	high	 importance	of	coumarins	as	
pharmacologically	valuable	compounds	and	specifically	as	potential	antiproliferative	agents,	
as	well	as	the	well-established	anticancer	activity	of	CA-4,	we	wished	to	develop	a	class	of	
compounds,	 we	 call	 1,4-triazolyl	 combretacoumarins,	 that	 was	 a	 composite	 of	 the	 two	
molecules.	 	 For	 this,	we	 contemplated	 on	 the	entire	 physiologically	 valuable	 structure	 of	
coumarin	and	the	functionally	relevant	moiety	of	CA-4.		We	chose	to	synthesize	and	evaluate	






















































































Initially,	 we	 synthesized	 the	 azide	 derivatives	 of	 4-hydroxycoumarin.	 	 Then,	 5-
ethynyl-1,2,3-trimethoxybenzene	 was	 made	 from	 5-(2,2-dibromovinyl)-1,2,3-
trimethoxybenzene.	 	 The	 latter	 was	 transformed	 from	 3,4,5-trimethoxybenzaldehyde.		
Finally,	we	combined	4-azidocoumarins	and	5-ethynyl-1,2,3-trimethoxybenzene	via	copper-
































approach	that	 is	being	developed	 in	our	 laboratories.	 	This	procedure	uses	(benzotriazol-
1yloxy)tris(dimethylamino)phosphonium	 hexafluorophosphate	 (BOP),	 a	 cheap,	















































chose	 entry	 3	 as	 general,	 optimized	 conditions	 to	 be	 used	 for	 synthesis	 of	 all	 of	 the	 4-






























































two	additional	 resonances.	 	One	appearing	at	d	 =	23.9	ppm	corresponding	 to	HMPA,	and	
another	at	d	=	33.9	ppm	corresponding	to	what	we	believe	is	intermediate	54	(Figure	13)	
formed	during	the	transformation	of	45	to	46.		As	the	reaction	was	allowed	to	proceed	over	
99	 minutes,	 a	 gradual	 decrease	 of	 54	 and	 BOP	 occurred,	 and	 the	 formation	 of	 HMPA	












On	 the	 basis	 of	 this	 observation,	 we	 propose	 a	 mechanism	 shown	 in	 Scheme	 5.		
Deprotonation	of	the	hydroxyl	in	45,	followed	by	reaction	at	the	phosphorus	atom	of	BOP,	










δ = 33.9 ppm (in MeCN)
PF6–
























δ = 35.7 ppm (in MeCN)
NH2
PF6–
δ = –145.8 ppm
PF6–











































































To	 synthesize	 our	 second	 reaction	 partner,	 5-ethynyl-1,2,3-trimethoxybenzene,	
initially	alkynylation	via	the	Ohira-Bestmann	approach	was	attempted	(Scheme	7).75,76		For	
the	 in	 situ	generation	of	 the	Ohira-Bestmann	reagent,	dimethyl	 acetylmethylphosphonate	





	 We	 then	 tried	 another	 reported	 procedure	 in	 which	 5-(2,2-dibromovinyl)-1,2,3-
trimethoxybenzene	 (57)	 was	 transformed	 into	 5-ethynyl-1,2,3-trimethoxybenzene	 (56)	
using	DBU	in	dry	MeCN	(Scheme	8).78		Notably,	compound	56	obtained	via	this	approach	has	
been	reported	 is	a	colorless	oil.	 	However,	 the	 literature	 indicates	 this	compound	to	be	a	
white	 solid.79	 	 The	 requisite	 precursor,	 57,	 was	 synthesized	 by	 reaction	 of	 55	 with	


































	 After	 obtaining	 both	 coupling	 partners,	 synthesis	 of	 the	 combretacoumarins	 was	
assessed	 using	 the	 following	 copper-based	 catalytic	 systems:	 CuSO4•5H2O/Na-ascorbate,	

























CH2Cl2, 0 oC for 0.5 h,











1.6 M n-BuLi in hexanes
THF, -78 oC for 4 h,































































Cat A Cat B Cat C
Catalysts tested
 27 
8	 10	mol	%	Cat	B	 3	:	1	CH2Cl2/MeOHh	 24	h,	rt	 Inc
c	






11	 10	mol	%	Cat	C	 3	:	1	CH2Cl2/MeOHh	 24	h,	50	°C	 72%
i,	42%j	
12	 10	mol	%	Cat	C	 CH2Cl2h	 48	h,	rt	 No	conversion	
13	 10	mol	%	Cat	C	 CH2Cl2h	 24	h,	50	°C	 70%i,	53%j	
14	 10	mol	%	Cat	C	 CH2Cl2h	 24	h,	80	°C	 77%i,	49%j	
15	 10	mol	%	Cat	C	 DCEh	 24	h,	65	°C	 Ince	















is	of	 isolated	and	chromatographically	purified	product.	 	 e	Reaction	was	 incomplete	(Inc),	













reached	 completion.	 	 We	 postulated	 that	 this	 may	 be	 due	 to	 the	 insolubility	 of	 4-
azidocoumarin	 (47)	 and	 5-ethynyl-1,2,3-trimethoxybenzene	 (56)	 in	 the	 solvent	 system.		
Therefore,	CH2Cl2	was	then	used	instead	of	t-butanol.		However,	as	seen	in	entries	4	and	5,	
























these	 reactions	 with	 Cat	 C	 (entries	 17–19).	 	 Reactions	 at	 room	 temperature	 in	 3	 :	 1	

















We	 then	decided	 to	 test	 the	 reaction	of	phenyl	 azide	 (66,	 PhN3),	 instead	of	 the	4-







































































CH2Cl2/MeOH.	 	 This	 was	 done	 to	 investigate	 the	 comparative	 reactivities	 of	 66	 and	
compounds	47–53	 in	 these	CuAAC	reactions.	 	66	was	prepared	 from	phenylboronic	acid	
(67)	with	NaN3	and	CuSO4•5H2O	in	MeOH,	using	a	reported	procedure.84		As	seen	in	Figure	
15,	compound	65	was	obtained	in	a	very	good	yield	within	3	h,	at	room	temperature.		This	











Compound	 N1	 N2	 N3	
R	=	H	(47)	 –0.346	 +0.257	 +0.003	
R=6-Cl	(48)	 –0.345	 +0.256	 +0.009		
R	=	6-Me	(49)	 –0.344	 +0.252	 +0.005	


































R	=	7-OMe	(51)	 –0.345	 +0.257	 –0.002	
R	=	6-Br	(52)	 –0.347	 +0.257	 +0.010	
R	=	6,8-DiCl	(53)	 –0.348	 +0.257	 +0.015	






















A	 NOESY	 spectrum	 of	 58	 in	 DMSO-d6	was	 obtained	 in	 order	 to	 confirm	 the	 1,4-
disubstitution	 pattern	 for	 the	 combretacoumarins	 (Figure	 16).	 	 This	 analysis	 showed	 a	
correlation	between	between	the	C5	triazolyl	proton (d = 9.35	ppm,	singlet)	to	the	chemically	





















































were	 insoluble	 in	 most	 solvents.	 	 They	 were	 evaluated	 by	 a	 live	 cell	 imaging-based	
differential	nuclear	 staining	 (DNS)	assay	against	 two	human	cancer	 cell	 lines:	CCRF-CEM	
leukemia	 cell	 line	 and	 MDA-MB-231	 triple-negative	 breast	 cancer	 cell	 line.	 	 In	 order	 to	
selectively	 differentiate	 between	 living	 and	 dead	 cells,	 DNS	 assays	 used	 two	 fluorescent	
nuclear	stains,	Hoechst	33342	and	propidium	iodide	(PI).85	
 35 
The	 initial	 tests	were	done	on	the	CCRF-CEM	leukemia	cell	 lines.	 	The	compounds	















with	 compounds	 58,	 61,	 and	 62.	 	 These	 compounds	 were	 also	 observed	 not	 to	 induce	
quantifiable	CEM	cell	death.	 	Cells	 treated	with	 compounds	63	and	64	were	observed	 to	
cause	43.69%	and	40.06%	cell	death,	respectively.		With	the	stock	solution	(highest	soluble	








Compounds	 Cell	line	 Incubation	(h)	 CC50(µM)	 Std.	Dev.	(µM)	
58	 CEM	 48	 	 NAa	
59	 CEM	 48	 	 NAa	
60	 CEM	 48	 	 NAa	
61	 CEM	 48	 	 NAa	
62	 CEM	 48	 	 NAa	
	
63	
CEM	 48	 	 NAa	
MB-231	 72	 	 NAa	
64	 CEM	 48	 	 NAa	
65	
CEM	 48	 30.57	 7.1345	
MB-231	 72	 50.55	 4.5425	
a	NA	=	Not	available;	unable	to	obtain	at	highest	soluble	concentration.	
Because	compounds	63	and	65	appeared	to	be	most	effective,	these	were	used	for	a	







CCRF-CEM	 cells	 were	 treated	 with	 30	 µM	 (CC50),	 60	 µM	 (CC100),	 and	 a	 high	 100	 µM,	
concentration	 of	 65	 for	 24	 h.	 	 This	 was	 followed	 with	 staining	 by	 annexin-fluorescein	
isothiocyanate	(FITC)	and	propidium	iodide	(PI).		Results	from	this	annexin	assay	indicated	
 37 






































more	 negative	 charge.		 In	 contrast	 to	 this,	 the	 remaining	 coumarins	 all	 had	 positive	
coefficients	 for	 the	N3.	 	These	results	seem	to	indicate	that	electron	density	at	 the	azides	
might	not	alone	account	for	the	reactivity	difference.		Compounds	58–65	were	evaluated	for	
 39 
antiviral	 and	 antiproliferative	 activity.	 	 Unfortunately,	 limitations	 in	 solubility	 of	 the	
combretacoumarins	were	the	major	hindering	factor	in	these	evaluations.		These	compounds	






















were	 obtained	 from	 commercial	 sources	 and	used	without	 further	 purification.	 	 1H	NMR	
spectra	were	obtained	at	500	MHz	in	CDCl3	and	are	referenced	to	7.26	ppm.		13C	NMR	spectra	































NH4Cl	 and	 transferred	 to	a	 separatory	 funnel	using	EtOAc.	 	The	mixture	was	partitioned	
between	EtOAc	and	water.		The	aqueous	layer	was	back	extracted	with	EtOAc	three	times.		
The	 combined	 organic	 layer	 was	 washed	 with	 brine,	 dried	 over	 anhydrous	 Na2SO4	 and	

























4-hydroxycoumarin	 (45,	 162	mg,	 1.00	mmol)	was	 placed	 in	 an	 oven-dried	 25	mL	
round	 bottomed	 flask	 equipped	 with	 a	 stir	 bar.	 	 To	 this,	 dry	 MeCN	 (10	 mL)	 and	 1,8-


















sequentially.	 	 The	 resulting	 homogenous,	 light-yellow	 solution	 was	 stirred	 at	 room	
temperature	 for	 10	 minutes.	 	 (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium	
hexafluorophosphate	(BOP,	531	mg,	1.20	mmol,	1.20	equiv.)	was	added	to	the	mixture	and	
stirred	for	1	h	at	room	temperature.		To	this	white	mixture,	NaN3	(195	mg,	3.00	mmol,	3.00	





Na2SO4	 and	 concentrated	 under	 reduced	 pressure.	 	 Purification	 was	 performed	 by	
chromatography	on	a	silica	gel	column	packed	in	hexanes,	and	eluted	with	hexanes	followed	


























































































equipped	 with	 a	 stir	 bar.	 	 To	 this,	 dry	 CH2Cl2	 (3.75	 mL)	 and	 5-ethynyl-1,2,3-





yellow	 mixture	 was	 transferred	 into	 a	 separatory	 funnel	 using	 CH2Cl2,	 and	 partitioned	
between	CH2Cl2	and	brine.		The	aqueous	layer	was	back	extracted	with	CH2Cl2	three	times.		










25% MeOH in CH2Cl2














Chromatography	 on	 a	 silica	 gel	 column	 packed	 in	 hexanes	 and	
sequentially	eluted	with	hexanes,	25%	EtOAc	in	hexanes,	40%	EtOAc	














EtOAc	 gave	 198	 mg	 (97%	 yield)	 of	 59.	 	 Because	 minor	





























EtOAc	 in	 hexanes,	 EtOAc,	 5%	MeOH	 in	EtOAC,	 10%	MeOH	 in	
EtOAc	and	20%	MeOH	in	EtOAc	gave	168	mg	(85%	yield)	of	60	
as	a	pale-yellow	solid.		Rf	(SiO2/25%	EtOAc	in	hexanes)	=	0.19.		



















EtOAc	 in	 hexanes,	 EtOAc,	 5%	MeOH	 in	 EtOAc,	 10%	MeOH	 in	
EtOAc	and	20%	MeOH	in	EtOAc	gave	184	mg	(94%	yield)	of	61	
as	a	pale-yellow	solid.		Rf	(SiO2/25%	EtOAc	in	hexanes)	=	0.19.		




































127.3,	 124.0,	 121.3,	 114.5,	 107.4,	 105.8,	 103.8,	 101.7,	 61.4,	 56.5,	 56.4.	 	 1H	 NMR	 showed	
minimal	degradation	of	the	product	after	an	overnight	13C	NMR	experiment	at	298.1	K	in	the	































EtOAc	 gave	 182	 mg	 (81%	 yield)	 of	 64	 as	 a	 yellow	 solid.	 	 Rf	
(SiO2/25%	EtOAc	in	hexanes)	=	0.13.		Mp:	224–226	°C	(dec.,	and	































mixture	 was	 flushed	 with	 nitrogen	 gas	 and	 stirred	 for	 3	 h	 at	 room	 temperature.	 	 TLC	
(SiO2/25%	 EtOAc	 in	 hexanes)	 indicated	 the	 reaction	 to	 be	 complete.	 	 The	 light-yellow	
mixture	was	 transferred	 into	 a	 separatory	 funnel	 using	 CH2Cl2,	 and	 partitioned	 between	
CH2Cl2	and	brine.	 	The	aqueous	layer	was	separated	and	back	extracted	with	CH2Cl2	three	
times.		The	combined	organic	layer	was	dried	over	anhydrous	Na2SO4	and	evaporated	under	











and	 1,8-diazabicyclo[5.4.0]undec-7-ene	 (DBU,	 90.0	 µL,	 0.60	 mmol,	 1.20	
equiv.)	were	 added	 sequentially.	 	The	 resulting	 homogenous,	 light-yellow	
solution	 was	 stirred	 at	 room	 temperature	 for	 10	 minutes.	 	 (Benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium	 hexafluorophosphate	 (BOP,	 265	mg,	 0.60	 mmol,	
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